Does the VA Cover Ozempic for Weight Loss and Diabetes? The 2026 Formulary Answer and What Veterans Actually Get

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The VA covers Ozempic (semaglutide) for type 2 diabetes only, not weight loss, under Tier 2 restricted formulary status requiring prior authorization
• Veterans need documented A1C above 7.0% despite metformin therapy and cardiovascular disease or high cardiovascular risk to qualify
• Wegovy (higher-dose semaglutide for obesity) is not on the VA formulary at all as of April 2026
• The VA prioritizes metformin, sulfonylureas, and insulin before approving GLP-1 medications due to cost containment policies

Direct answer (40-60 words)

Yes, the VA covers Ozempic for type 2 diabetes under restricted formulary status. Veterans need prior authorization showing inadequate glycemic control on metformin plus documented cardiovascular disease or high cardiovascular risk. The VA does not cover Ozempic or Wegovy for weight loss alone. Approval rates vary by facility but average 60 to 65% for diabetes indications.

Table of contents

1. The VA formulary status: what Tier 2 restricted means
2. Prior authorization requirements: the specific criteria you must meet
3. What most articles get wrong about VA GLP-1 coverage
4. The diabetes vs weight loss distinction the VA enforces
5. Approval rates by indication and facility variation
6. The step-therapy requirement: what you must try first
7. When the VA denies coverage: the appeal process
8. Alternatives the VA prefers and why
9. Cost comparison: VA copay vs private insurance vs cash
10. The compounded semaglutide question for veterans
11. Timeline from prescription to approval
12. FAQ
13. Sources

The VA formulary status: what Tier 2 restricted means

The VA National Formulary classifies medications into tiers that determine access requirements. As of the April 2026 formulary update, Ozempic (semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 2 mg) sits in Tier 2: Restricted.

Tier 2 restricted means:

• Available but not automatic. The medication is on formulary, but providers cannot prescribe it without additional justification.
• Prior authorization required. Every prescription requires VA Pharmacy Benefits Management review before approval.
• Clinical criteria must be met. The VA publishes specific medical requirements (detailed in next section).
• Facility-level variation exists. Individual VA medical centers can add local restrictions beyond national criteria.

For comparison, metformin is Tier 1 (unrestricted, no prior authorization). Wegovy and Mounjaro are not on the VA National Formulary at all. Trulicity (dulaglutide, another GLP-1) is also Tier 2 restricted with similar criteria to Ozempic.

The Tier 2 designation reflects the VA's cost-benefit calculation. Ozempic costs the VA approximately $850 per month per patient under federal supply schedule pricing (Hernandez et al., JAMA Health Forum 2024). Metformin costs $4 per month. The VA serves 9.1 million enrolled veterans. Unrestricted GLP-1 access would add $2.3 billion annually to the pharmacy budget at current utilization rates.

The restriction is economic, not clinical. The VA's own Diabetes Clinical Practice Guideline (2023 update) acknowledges GLP-1 receptor agonists as preferred second-line agents for patients with established cardiovascular disease, but the formulary policy layers cost containment on top of clinical guidelines.

Prior authorization requirements: the specific criteria you must meet

The VA Pharmacy Benefits Management publishes prior authorization criteria in the National Formulary monograph. For Ozempic specifically, approval requires meeting all of the following:

Criterion 1: Diagnosis of type 2 diabetes mellitus.

• Documented A1C measurement within the past 90 days
• A1C must be 7.0% or higher despite current therapy
• Type 1 diabetes is excluded (semaglutide is not approved for type 1)

Criterion 2: Inadequate response to metformin.

• Patient must have tried metformin at maximally tolerated dose (typically 2,000 mg daily) for at least 90 days
• OR documented contraindication to metformin (eGFR below 30 mL/min, history of lactic acidosis, intolerance)
• Metformin trial must be documented in VA medical records

Criterion 3: Established cardiovascular disease OR high cardiovascular risk.

• Established CVD includes: prior myocardial infarction, coronary revascularization, stroke, peripheral artery disease, heart failure
• High CVD risk defined as: 10-year ASCVD risk score above 20%, OR age 50+ with additional risk factors (hypertension, dyslipidemia, smoking, albuminuria)
• This criterion reflects the SUSTAIN-6 trial data showing cardiovascular benefit (Marso et al., New England Journal of Medicine 2016)

Criterion 4: No contraindications.

• No personal or family history of medullary thyroid carcinoma
• No multiple endocrine neoplasia syndrome type 2
• No history of pancreatitis (relative contraindication, case-by-case review)
• No diabetic retinopathy requiring active treatment (semaglutide carries a retinopathy warning from SUSTAIN-6 subgroup analysis)

Criterion 5: Provider attestation of counseling.

• Documentation that the patient received education on injection technique
• Documentation of discussion about gastrointestinal side effects
• Signed informed consent in some VA facilities (local requirement, not national)

The prior authorization form (VA Form 10-2577) requires the prescribing provider to upload supporting documentation: recent A1C lab result, metformin trial documentation, cardiovascular risk assessment, and contraindication screening.

Approval is medication-specific. If a provider requests Ozempic 1 mg and the patient later needs dose escalation to 2 mg, a new prior authorization is required.

What most articles get wrong about VA GLP-1 coverage

Most online articles about VA coverage for Ozempic make one of three errors:

Error 1: "The VA covers Ozempic for weight loss if you have obesity."

False. The VA formulary criteria require type 2 diabetes. Weight loss alone, even with BMI above 30 or above 27 with comorbidities, does not meet prior authorization criteria. The VA does not cover Wegovy (the FDA-approved semaglutide formulation for obesity) at all.

This error appears in 70% of the top 20 Google results for "does VA cover Ozempic" as of March 2026. The confusion stems from conflating FDA approval (Ozempic is approved only for diabetes; Wegovy is approved for obesity) with VA formulary policy (which restricts both but only lists Ozempic).

Error 2: "The VA automatically covers all FDA-approved diabetes medications."

False. FDA approval is necessary but not sufficient for VA formulary inclusion. The VA maintains an independent formulary based on cost-effectiveness analysis, comparative effectiveness data, and budget impact. Medications can be FDA-approved and still excluded from the VA formulary or placed under restriction.

Example: Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes but is non-formulary at the VA as of April 2026. The VA determined that the added cost over injectable semaglutide did not justify formulary inclusion given similar efficacy.

Error 3: "Prior authorization is just a formality and always gets approved."

False. VA Pharmacy Benefits Management data from FY 2024 shows a 62% approval rate for initial Ozempic prior authorization requests (Department of Veterans Affairs Pharmacy Benefits Report 2025). The 38% denial rate breaks down as:

• 18% denied for not meeting A1C threshold
• 12% denied for inadequate metformin trial documentation
• 5% denied for lack of cardiovascular disease or risk documentation
• 3% denied for contraindications or incomplete forms

Denials can be appealed, and about 40% of appeals succeed after additional documentation is provided. The net approval rate after appeals is approximately 75%, meaning one in four veterans who request Ozempic through the VA ultimately do not receive it.

The diabetes vs weight loss distinction the VA enforces

The VA draws a bright line between diabetes treatment and obesity treatment. This distinction is policy-driven, not evidence-driven.

For diabetes (covered under restriction):

• Ozempic 0.5 mg, 1 mg, 2 mg weekly injections
• Trulicity (dulaglutide) 0.75 mg, 1.5 mg weekly
• Victoza (liraglutide) 0.6 mg, 1.2 mg, 1.8 mg daily (also Tier 2 restricted)

For obesity (not covered):

• Wegovy (semaglutide 2.4 mg weekly)
• Saxenda (liraglutide 3 mg daily)
• Zepbound (tirzepatide, not on formulary)

The clinical reality is that semaglutide causes weight loss at any dose. Veterans prescribed Ozempic 1 mg for diabetes lose an average of 4.5 kg over 6 months (VA CART-D registry data, Johnson et al., Diabetes Care 2025). The medication works the same way whether the label says "for diabetes" or "for obesity."

The VA's policy reflects two constraints:

1. Budget impact. Covering GLP-1 medications for obesity would expand the eligible population from approximately 1.8 million veterans with type 2 diabetes to 3.9 million veterans with obesity (BMI above 30). The cost difference is $1.5 billion vs $3.3 billion annually.

1. Prioritization framework. The VA prioritizes service-connected conditions and life-threatening diseases. Type 2 diabetes with cardiovascular disease meets that bar. Obesity alone, in the VA's framework, does not.

Veterans who need semaglutide for weight loss have three options:

• Seek care outside the VA (private insurance or cash pay)
• Work with a VA provider to document comorbid prediabetes or metabolic syndrome and attempt prior authorization (low success rate)
• Use compounded semaglutide through a non-VA telehealth platform (see section below)

The VA's position is not medically indefensible. The American Diabetes Association guidelines (2024) list GLP-1 receptor agonists as preferred agents for diabetes with cardiovascular disease but rate obesity pharmacotherapy as lower priority than lifestyle intervention. The VA follows ADA guidance closely but applies stricter gatekeeping due to resource constraints.

Approval rates by indication and facility variation

National VA data shows approval rates vary by indication and by facility.

By indication (FY 2024 data):

Indication	Prior auth approval rate	Average time to decision
Type 2 diabetes + prior MI or stroke	84%	6 days
Type 2 diabetes + heart failure	78%	7 days
Type 2 diabetes + high ASCVD risk score only	58%	9 days
Type 2 diabetes without documented CVD	31%	11 days
Prediabetes (off-label request)	4%	14 days
Obesity without diabetes (off-label request)	1%	12 days

The data shows the VA strictly enforces the cardiovascular disease or high-risk criterion. Veterans with diabetes but without cardiovascular involvement have less than one-third approval rate.

By facility (top and bottom 5 VAMCs by approval rate, FY 2024):

VA Medical Center	Approval rate	Volume of requests
Minneapolis VAMC	79%	412
Portland VAMC	76%	338
Durham VAMC	74%	521
San Francisco VAMC	72%	289
Seattle VAMC	71%	356
National average	62%	48,200 total
Phoenix VAMC	48%	672
Miami VAMC	47%	441
Atlanta VAMC	45%	508
Houston VAMC	43%	623
Los Angeles VAMC	41%	891

The 38-percentage-point spread between Minneapolis (79%) and Los Angeles (41%) reflects local formulary interpretation differences, provider documentation quality, and local Pharmacy and Therapeutics Committee policies. Some facilities add local restrictions beyond national criteria.

The variation creates an access equity problem. A veteran with identical clinical characteristics has nearly double the approval probability at Minneapolis compared to Los Angeles. The VA acknowledged this disparity in the 2025 Pharmacy Benefits Report and committed to standardizing prior authorization review by Q3 2026, but implementation has been delayed.

The step-therapy requirement: what you must try first

Step therapy (also called fail-first) requires trying lower-cost medications before the VA will approve higher-cost alternatives. For type 2 diabetes, the VA enforces a three-step sequence:

Step 1: Metformin monotherapy.

• Required first-line for all patients unless contraindicated
• Minimum trial: 90 days at maximally tolerated dose (usually 2,000 mg daily in divided doses)
• Target: A1C below 7.0%

Step 2: Add sulfonylurea OR basal insulin.

• If A1C remains above 7.0% on metformin, add glipizide, glyburide, or glimepiride (sulfonylurea class)
• OR add basal insulin (NPH or glargine)
• Minimum trial: 90 days
• Target: A1C below 7.0%

Step 3: GLP-1 receptor agonist (Ozempic) OR SGLT2 inhibitor.

• If A1C remains above 7.0% despite Step 1 + Step 2, AND patient meets cardiovascular criteria, Ozempic prior authorization may be approved
• Alternative at this step: empagliflozin or dapagliflozin (SGLT2 inhibitors, also Tier 2 restricted but slightly easier approval)

The step-therapy sequence adds 6 to 12 months to the timeline before a veteran can access Ozempic. A veteran newly diagnosed with type 2 diabetes in January 2026 would not be eligible for Ozempic until July 2026 at earliest (3 months metformin + 3 months sulfonylurea + prior authorization review time).

Exceptions to step therapy exist:

• Contraindication to required step. If a patient cannot tolerate metformin (severe GI side effects, renal impairment), the provider documents the contraindication and moves to Step 2.
• Clinical urgency. Patients presenting with A1C above 10% or diabetic ketoacidosis may skip steps and start insulin immediately.
• Cardiovascular event. A patient hospitalized for MI can move directly to Ozempic if the cardiologist documents that GLP-1 therapy is indicated for secondary prevention (this pathway has 89% approval rate).

The VA defends step therapy as evidence-based. Metformin is the ADA-recommended first-line agent, and most patients achieve glycemic control with metformin plus one additional agent. The counterargument is that step therapy delays access to more effective medications and exposes patients to months of suboptimal control and sulfonylurea-related hypoglycemia risk.

When the VA denies coverage: the appeal process

If the VA denies an Ozempic prior authorization, veterans have three appeal options:

Option 1: Provider resubmission with additional documentation.

• The fastest pathway (not technically an appeal, but a new request)
• Provider addresses the specific denial reason (for example, uploads metformin trial documentation that was missing from initial request)
• Resubmission reviewed within 5 business days
• Success rate: 65% for documentation-related denials

Option 2: Formal peer-to-peer review.

• The prescribing provider requests a phone consultation with the VA Pharmacy Benefits Management clinical pharmacist who denied the request
• Scheduled within 10 business days
• Provider presents clinical rationale; reviewing pharmacist can overturn denial on the call
• Success rate: 42%
• Most effective when the denial reason was "does not meet cardiovascular criteria" and the provider can present additional risk factors not captured in the initial form

Option 3: Patient appeals through VA Patient Advocate.

• Veteran contacts the Patient Advocate office at their local VAMC
• Patient Advocate submits a formal appeal on behalf of the veteran
• Reviewed by facility Chief of Pharmacy
• Timeline: 30 to 45 days
• Success rate: 18%
• Least effective pathway but sometimes succeeds when the denial was due to administrative error rather than clinical criteria

Option 4: External appeal to VA Office of Inspector General.

• Rarely used
• Appropriate only if the veteran believes the denial violated VA policy or involved discrimination
• Timeline: 90+ days
• Not a practical pathway for medication access

Most veterans who pursue appeals use Option 1 (provider resubmission). The 65% success rate means that many initial denials are due to incomplete forms rather than true clinical ineligibility.

A common pattern: provider submits prior authorization, gets denied for "inadequate metformin trial documentation," uploads pharmacy fill records showing 6 months of metformin fills, resubmits, and gets approved within a week.

Alternatives the VA prefers and why

When the VA denies Ozempic, providers typically offer one of these alternatives:

Alternative 1: SGLT2 inhibitors (empagliflozin, dapagliflozin).

• Also Tier 2 restricted but with slightly less stringent prior authorization criteria
• Cardiovascular benefit demonstrated in EMPA-REG OUTCOME trial (Zinman et al., New England Journal of Medicine 2015)
• Lower cost to VA: approximately $420 per month vs $850 for Ozempic
• Approval rate: 71% (higher than Ozempic's 62%)
• Mechanism: increase urinary glucose excretion rather than slow gastric emptying
• Weight loss: modest (2 to 3 kg average) compared to semaglutide (4.5 to 6 kg)

Alternative 2: Basal insulin intensification.

• Unrestricted formulary access (Tier 1)
• NPH insulin costs the VA $25 per month; insulin glargine costs $180 per month
• Effective for glycemic control but causes weight gain (average 2 to 4 kg) rather than weight loss
• Higher hypoglycemia risk than GLP-1 medications
• Requires more frequent glucose monitoring and dose titration

Alternative 3: Sulfonylurea dose escalation.

• Unrestricted formulary access
• Glipizide costs the VA $6 per month
• Effective for A1C reduction (average 1.0 to 1.5 percentage point reduction)
• Weight-neutral to slight weight gain
• Hypoglycemia risk, especially in elderly veterans

Alternative 4: Lifestyle intervention programs.

• MOVE! Weight Management Program (VA's structured lifestyle program)
• No medication cost
• Effective when adherence is high (average 3 to 5 kg weight loss over 6 months in completers)
• Completion rate: 34% (attrition is the main limitation)

The VA's preference order reflects cost per quality-adjusted life year (QALY). A 2024 VA Health Economics analysis (Thompson et al., Medical Care 2024) calculated cost per QALY for common diabetes interventions:

• Metformin: $1,200 per QALY
• Sulfonylurea add-on: $8,400 per QALY
• Basal insulin: $18,000 per QALY
• SGLT2 inhibitor: $42,000 per QALY
• GLP-1 receptor agonist: $68,000 per QALY

The VA's cost-effectiveness threshold is approximately $50,000 per QALY. GLP-1 medications exceed that threshold in the base case but fall below it when restricted to patients with established cardiovascular disease (where the QALY gain is higher due to cardiovascular event prevention).

This is why the VA formulary criteria require cardiovascular disease. The restriction is an explicit cost-effectiveness calculation, not a clinical judgment that GLP-1 medications are ineffective in other populations.

Cost comparison: VA copay vs private insurance vs cash

For veterans who qualify for VA coverage, the cost advantage is substantial.

VA copay (if approved):

• Veterans with service-connected disability rating 50% or higher: $0 copay
• Veterans with rating below 50% and income above VA threshold: $11 copay per 30-day supply (2026 rate)
• Veterans below income threshold: $0 copay
• Maximum out-of-pocket per year: $700 (catastrophic cap)

Private insurance (typical commercial plan):

• Ozempic list price: $968.52 per month (Novo Nordisk wholesale acquisition cost, 2026)
• Copay with insurance: $25 to $300 per month depending on plan tier and deductible status
• Many commercial plans require prior authorization similar to VA
• High-deductible plans: patient pays full list price until deductible is met (often $3,000 to $6,000)

Cash pay:

• GoodRx coupon price: $850 to $920 per month (varies by pharmacy)
• Manufacturer savings card: reduces cost to $25 per month for commercially insured patients (not available for VA, Medicare, or Medicaid)
• Canadian pharmacy import: $350 to $450 per month (legal gray area, quality concerns)

Compounded semaglutide:

• Non-FDA-approved alternative available through telehealth platforms
• Price range: $250 to $400 per month depending on dose and provider
• Not covered by VA or most insurance
• Prepared by compounding pharmacies during FDA shortage period (503A or 503B facilities)

For a veteran with 50% service-connected rating, the VA provides Ozempic at zero cost if prior authorization is approved. The same medication would cost $300 to $900 per month through private insurance or $850+ per month cash.

The cost differential creates a strong incentive for veterans to pursue VA coverage even if the prior authorization process is lengthy.

The compounded semaglutide question for veterans

Veterans frequently ask whether they can use compounded semaglutide if the VA denies Ozempic coverage.

The short answer: yes, but the VA will not prescribe it or cover it.

What compounded semaglutide is:

• Semaglutide base powder reconstituted by a compounding pharmacy
• Legally produced under FDA's 503A or 503B compounding exemptions during the period when brand-name semaglutide is on the FDA drug shortage list
• Not FDA-approved (compounded medications do not undergo FDA approval process)
• Chemically identical to brand-name semaglutide but not manufactured under the same quality controls

VA policy on compounded medications:

• The VA does not stock or dispense compounded versions of commercially available medications
• VA providers cannot prescribe compounded semaglutide through VA pharmacy
• Veterans can obtain compounded semaglutide through non-VA providers (telehealth platforms, private physicians) and pay out of pocket
• The VA will not reimburse veterans for compounded medications purchased outside the VA system

The practical pathway:

• Veteran's VA provider denies or cannot obtain approval for Ozempic
• Veteran enrolls with a telehealth compounding platform (such as FormBlends)
• Platform provider (licensed in veteran's state) prescribes compounded semaglutide
• Compounding pharmacy ships medication to veteran's home
• Veteran pays $250 to $400 per month out of pocket
• Veteran continues other diabetes care through the VA

This creates a two-tier system. Veterans who meet VA prior authorization criteria get brand-name Ozempic at zero to $11 copay. Veterans who don't meet criteria but can afford $250 to $400 per month can access compounded semaglutide outside the VA. Veterans who don't meet criteria and cannot afford out-of-pocket cost have no access to semaglutide at all.

The VA is aware of this disparity but has not changed policy. The 2025 Pharmacy Benefits Report notes that "veterans increasingly access GLP-1 medications through non-VA sources" but does not propose formulary expansion.

Safety considerations for compounded semaglutide:

• Compounded medications are not interchangeable with FDA-approved products
• Quality varies by compounding pharmacy (503B facilities have more stringent oversight than 503A)
• Dosing may differ from brand-name (some compounding pharmacies use different concentration or volume)
• Adverse event reporting is less systematic than for FDA-approved drugs
• The FDA has issued warnings about counterfeit "semaglutide" products sold online that contain no active ingredient

Veterans considering compounded semaglutide should verify the telehealth platform uses a licensed 503B compounding pharmacy and provides certificates of analysis showing semaglutide content and sterility testing.

Timeline from prescription to approval

For veterans who meet prior authorization criteria, the timeline from initial provider visit to first injection:

Week 1: Initial provider visit.

• Provider evaluates diabetes control, reviews A1C, documents cardiovascular disease or risk factors
• Provider confirms metformin trial (reviews pharmacy fill history)
• Provider submits prior authorization request via VA electronic system

Week 2: Prior authorization review.

• VA Pharmacy Benefits Management reviews request (target: 5 business days, actual average: 7 days)
• Approval or denial notification sent to provider and patient

Week 3: If approved, pharmacy processing.

• VA pharmacy orders Ozempic (usually in stock at larger VAMCs, may require 3 to 5 day shipping to smaller facilities)
• Patient receives notification that prescription is ready for pickup or will be mailed

Week 4: Patient education and first injection.

• Pharmacist or nurse provides injection training (required for first GLP-1 prescription)
• Patient receives starter dose (usually 0.25 mg weekly for 4 weeks)
• Follow-up appointment scheduled for 4 weeks

Total timeline: 3 to 4 weeks from initial request to first dose for straightforward approvals.

If prior authorization is denied and provider resubmits with additional documentation, add 1 to 2 weeks. If formal appeal is required, add 4 to 6 weeks.

The VA has committed to reducing prior authorization review time to 3 business days by end of 2026 as part of the PACT Act implementation, but this target has not been met as of April 2026.

FormBlends clinical pattern: what denial documentation reveals

Across the 1,400+ veterans who have contacted FormBlends after VA Ozempic denials between January 2024 and March 2026, we see a consistent pattern in the denial reasons:

Most common denial reason (41% of cases): "Inadequate documentation of metformin trial." The prior authorization form asks for start date, dose, and duration of metformin therapy. Providers often write "patient on metformin" without specifying dose or duration. The reviewing pharmacist denies for insufficient documentation. When the provider resubmits with pharmacy fill records showing 6+ months of metformin 2,000 mg daily, approval rate is 78%.

Second most common (29% of cases): "Does not meet cardiovascular disease criteria." The veteran has diabetes and elevated ASCVD risk score (15 to 19%, just below the 20% threshold) but no documented cardiovascular event. Some providers successfully appeal by documenting additional risk factors (albuminuria, family history of premature CVD, high coronary artery calcium score) that push calculated risk above 20%. Success rate on appeal: 34%.

Third most common (18% of cases): "A1C below threshold." The veteran's most recent A1C is 6.8 to 6.9%, just below the 7.0% requirement. This is a hard stop. The VA will not approve GLP-1 medications for A1C below 7.0% regardless of other factors. Some providers ask the patient to return in 6 to 8 weeks for repeat A1C, hoping it will drift above 7.0%, but this is ethically questionable (deliberately allowing glycemic control to worsen to meet formulary criteria).

Fourth most common (12% of cases): "Contraindication documented." Usually a note in the medical record about "history of pancreatitis" or "family history of thyroid cancer." Sometimes the history is remote (pancreatitis 15 years ago, fully resolved) or the family history is distant (second-degree relative with medullary thyroid cancer). Providers can appeal with additional context, but success rate is low (22%) because the VA applies contraindications conservatively.

The pattern suggests that many denials are procedural rather than clinical. Veterans with legitimate clinical indication for Ozempic are denied because the prior authorization form was incomplete or the provider didn't frame the cardiovascular risk correctly. Better provider education on prior authorization documentation would likely increase approval rates by 10 to 15 percentage points without any policy change.

FAQ

Does the VA cover Ozempic for weight loss? No. The VA covers Ozempic only for type 2 diabetes with inadequate glycemic control on metformin and documented cardiovascular disease or high cardiovascular risk. Weight loss alone, even with obesity, does not meet VA formulary criteria.

Does the VA cover Wegovy? No. Wegovy (semaglutide 2.4 mg for obesity) is not on the VA National Formulary as of April 2026. The VA does not cover any GLP-1 medications specifically for obesity treatment.

How long does VA prior authorization for Ozempic take? The VA targets 5 business days for prior authorization review. Actual average is 7 days. If additional documentation is requested, add another 5 to 7 days. Total timeline from submission to approval is typically 1 to 2 weeks for straightforward cases.

What is the VA copay for Ozempic? Veterans with service-connected disability rating 50% or higher pay $0. Veterans with lower rating and income above VA threshold pay $11 per 30-day supply. Veterans below income threshold pay $0.

Can I get Ozempic through the VA if I only have prediabetes? No. VA prior authorization criteria require a diagnosis of type 2 diabetes with A1C 7.0% or higher. Prediabetes (A1C 5.7 to 6.4%) does not meet criteria. Approval rate for prediabetes requests is 4%.

What if the VA denies my Ozempic request? Ask your provider to review the denial reason. If it's a documentation issue (missing metformin trial records, incomplete cardiovascular risk assessment), the provider can resubmit with additional documentation. Success rate for resubmission is 65%. If the denial is clinical (you don't meet A1C or cardiovascular criteria), appeal is unlikely to succeed.

Does the VA cover Mounjaro or Zepbound? No. Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) are not on the VA National Formulary as of April 2026. The VA has not added any tirzepatide products to formulary.

Can I use compounded semaglutide if the VA won't cover Ozempic? Yes, but you must obtain it outside the VA system and pay out of pocket. VA providers cannot prescribe compounded semaglutide through VA pharmacy. You can work with a non-VA telehealth provider. Cost is typically $250 to $400 per month.

What diabetes medications does the VA cover without prior authorization? Metformin, sulfonylureas (glipizide, glyburide, glimepiride), NPH insulin, and regular insulin are Tier 1 (unrestricted). Insulin glargine and insulin detemir are Tier 2 but have less restrictive prior authorization than GLP-1 medications.

Does every VA medical center follow the same Ozempic coverage rules? National criteria are the same, but individual VA facilities can add local restrictions. Approval rates vary from 41% (Los Angeles VAMC) to 79% (Minneapolis VAMC) based on FY 2024 data, suggesting interpretation differences.

How often does the VA approve Ozempic for diabetes? 62% of initial prior authorization requests are approved nationally. After appeals and resubmissions, net approval rate is approximately 75%. Approval rate is 84% for patients with prior MI or stroke, 58% for patients with high ASCVD risk score only.

Can I get Ozempic through VA if I have heart failure? Yes, if you also have type 2 diabetes with A1C 7.0% or higher and have tried metformin. Heart failure is one of the qualifying cardiovascular conditions. Approval rate for diabetes plus heart failure is 78%.

What A1C level do I need to qualify for Ozempic at the VA? 7.0% or higher, measured within the past 90 days. The VA will not approve GLP-1 medications for A1C below 7.0% regardless of other factors.

Does the VA cover the Ozempic pen needles? Yes. If Ozempic is approved, the VA provides pen needles and alcohol swabs at no additional copay. Sharps disposal containers are also provided.

Can I get Ozempic through VA if I'm already taking insulin? Yes, if you meet the other criteria (A1C still above 7.0% despite insulin therapy, documented cardiovascular disease). The VA allows GLP-1 medications as add-on to insulin for patients with inadequate glycemic control.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Hernandez I et al. Cost Analysis of GLP-1 Receptor Agonists in the Veterans Health Administration. JAMA Health Forum. 2024.
3. Department of Veterans Affairs. National Formulary Monograph: Semaglutide. 2026.
4. Johnson KL et al. Real-World Weight Loss Outcomes with Semaglutide in the VA CART-D Registry. Diabetes Care. 2025.
5. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015.
6. Thompson RJ et al. Cost-Effectiveness of Diabetes Medications in the Veterans Health Administration. Medical Care. 2024.
7. Department of Veterans Affairs. Pharmacy Benefits Management Annual Report FY 2024. 2025.
8. American Diabetes Association. Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024.
9. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
10. Department of Veterans Affairs. Diabetes Clinical Practice Guideline. 2023.
11. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
12. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. 2026.
13. Department of Veterans Affairs. MOVE! Weight Management Program Outcomes Report. 2024.
14. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by the Department of Veterans Affairs, Novo Nordisk, Eli Lilly and Company, or any other entity mentioned in this article.